Form 4: VolitionRX Executive Ann-Louise Batchelor Receives Stock Award in Lieu of Cash Compensation

Ann-Louise Batchelor, Group Chief Marketing Officer of VolitionRX Ltd, received 14,233 restricted stock units (RSUs) in lieu of cash compensation on March 1, 2025.

Summary

• On March 1, 2025, Ann-Louise Batchelor, Group Chief Marketing Officer of VolitionRX Ltd, was granted 14,233 restricted stock units (RSUs) under the company's 2024 Stock Incentive Plan.
• These RSUs were awarded in place of cash compensation.
• The RSUs vest in three installments of 4,745, 4,744, and 4,744 units on March 1, 2025, April 1, 2025, and May 1, 2025, respectively.
• The RSUs are also subject to further time-based vesting in a single installment on March 1, 2026, contingent upon continued service.
• Upon vesting and settlement, Batchelor will receive common stock shares equal to the number of vested RSUs.
• Following the transaction, Batchelor directly owns 128,942 shares of VolitionRX Ltd common stock and indirectly owns 29,406 shares through a spouse.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a standard executive compensation practice that aligns interests but doesn't indicate significant positive or negative news.

Positives

• The grant of RSUs aligns the executive's interests with those of the shareholders.
• The vesting schedule incentivizes continued service and contribution to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the RSUs.

Industry Context

This is a standard practice for compensating executives in publicly traded companies, aligning their interests with shareholders through equity ownership.

Comparison to Industry Standards

• Granting restricted stock units (RSUs) to executives is a common practice among publicly traded companies, including biotechnology firms like VolitionRX.
• Companies such as Exact Sciences and Guardant Health also utilize equity-based compensation to incentivize their leadership teams.
• The vesting schedules and amounts of RSUs typically vary based on the executive's role, performance, and company's overall compensation strategy.
• The use of RSUs in lieu of cash compensation can help preserve cash flow for research and development activities, which is crucial for companies in the biotechnology sector.

Stakeholder Impact

• Shareholders may view the RSU grant as a positive sign, aligning executive interests with long-term company performance.
• Employees may see this as a standard compensation practice for executives.

Key Dates